The EPO published patent application EP3787647A1 covering compositions and methods using de-differentiated fibroblast-conditioned media for treating or preventing intervertebral disc degeneration. The application, filed by FibroBiologics, Inc. (inventors: O'Heeron, Ichim), is classified under IPC codes A61K 35/28, A61L 27/38, A61K 35/33, and C12N 5/077. The designated states include AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Patent publication does not impose compliance obligations on third parties. Companies developing regenerative medicine therapies for disc degeneration or related fibroblast-based treatments within the EU should review the patent claims to assess potential freedom-to-operate implications. The patent grants FibroBiologics exclusive rights to the claimed compositions and methods in designated EU states.